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A COMPARISON OF TRIPLE COMINATION ORAL SEDATION REGIMINES FOR 
PEDIATRIC DENTAL TREATMENT 
By: Brett Henderson, DMD  
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
in Dentistry at Virginia Commonwealth University. 
Virginia Commonwealth University, May 2019 
Thesis Advisor: William O. Dahlke, DMD 
Chairman, Associate Professor, Department of Pediatric Dentistry  
 
Purpose: Compare the efficacy of two benzodiazepines (diazepam or midazolam) in 
combination with meperidine and hydroxyzine for pediatric dental sedation. 
Methods: A randomized, double blind observation study of behaviors and outcomes related to 
two sedation groups. Frankl and Houpt behavior scores were recorded at three time points: 
injection time, initiation of treatment and at the end of treatment.  Postoperative phone call 
surveys were conducted within eight hours of discharge to assess sleep, activity, and behavior. 
Results: A total of 40 sedation subjects were included in the study, of which 20 were treated 
with diazepam triple Combination (Di+M+H) and 20 with midazolam triple regime (Mi+M+H). 
Treatment was successful for 45% of cases with midazolam and 70% with diazepam (P 
value=.20). Houpt sleep scores were significantly higher for diazepam than midazolam at 
viii 
 
 
 
injection (P-value=.0043) and during treatment (P-value=.0152). Although Frankl scores, Houpt 
move and Houpt cry scores tended to favor diazepam, none were statistically significantly 
different. More abnormal behavior was reported with midazolam, though not statistically 
significant (35% vs 6%, P-value=.0854).  Postoperative sleep time was longer for midazolam, 
but not significantly different (median sleep time: 61 vs 45 minutes, P-value=.2071). 
Conclusion: The diazepam, meperidine, hydroxyzine triple combination sedation regimen shows 
promising results as a successful alternative to midazolam triple combination. Longer 
postoperative monitoring may be required with diazepam, but this study has shown postoperative 
sleep times to be less than previously reported. Larger sample size is needed to determine if the 
current trend will be maintained. 
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Introduction 	
Triple combination sedation regimens have been a mainstay in pediatric dentistry for 
many years to allow for moderate sedation of pre-cooperative and anxious pediatrics patients.1 
Over the years, the drug combinations have changed, with the current triple combination of 
midazolam, meperidine, and hydroxyzine being the most studied and widely accepted form of 
triple combination as a result of the ability to reverse both the opioid and benzodiazepine drugs 
in the event of adverse reactions.2 
 Prior to the midazolam triple, chloral hydrate with hydroxyzine and meperidine was the 
triple regimen of choice, but without a reversal drug for chloral hydrate, higher rates of emesis, 
and increased likelihood of respiratory depression, alternatives were sought to improve efficacy 
and safety.3,4  Studies of midazolam across numerous delivery routes and drug combinations in 
pediatrics have been linked with agitation3, yet there is significant research claiming that oral 
versed is a superior or equal pediatric sedative when compared with oral diazepam.5   
 To date, there is little evidence comparing midazolam versus diazepam in a triple 
combination sedation.2  One of the primary reasons for studying the various combinations of 
benzodiazepine triple regimens is related to the history of midazolam extrapyramidal and 
paradoxical effects related to agitation and hyperactivity, both are believed to be linked to the 
rapid uptake and quicker half-life of midazolam, i.e. faster withdrawal symptoms.6  A 2012 
Cochran review showed a weak effectiveness for midazolam, and with the increase incidence of 
general anesthesia for pediatric dental procedures, many practitioners are reducing the amount of 
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pediatric oral sedation procedures.2,7   These issues pose the dilemma of discovering a better 
alternative to the current triple combination therapy.  
 When using a modern triple combination sedation regimen, a narcotic such as meperidine 
is used for pain control in conjunction with an antiemetic/antihistamine such as hydroxyzine, 
along with a sedative benzodiazepine such as midazolam or diazepam.  Each of these 
medications alone may produce sedative effects and when used in combination may potentiate 
even greater sedative effects.8–12  Meperidine is a synthetic opioid analgesic that causes central 
nervous system (CNS), cardiovascular, and respiratory depression.  It is a mu receptor agonist 
that primarily produces analgesia and sedation that can lower seizure threshold and induce 
histamine release.   Oral meperidine analgesia can be obtained within 15 minutes of 
administration; peak analgesia onset is 60-120 minutes with a half-life of 2.5 to 5 hours.11,13–15  
Therapeutic doses of meperidine (1 - 2mg/kg) may induce euphoria & reduce shivering, while 
excessive doses may induce dysphoria and convulsions.15 Hydroxyzine is a H1 antagonist 
providing antihistamine, antipruritic, and antiemetic properties.  Hydroxyzine is considered a 
sedative, CNS depressant and may provide relief from anxiety, itching, skeletal muscle 
relaxation, analgesia, and bronchodilation.  Hydroxyzine oral onset is 15-30 minutes, maximum 
clinical effects takes place by 2 hours, with a duration of sedative effects lasting 3 to 4 hours, 
finally the half-life of antipruritic effects are 14-20 hours.8,12,16,17  
 Benzodiazepines achieve their CNS depressant anxiolytic effect by positive allosteric 
modulation of the gamma amino butyric acid (GABA)A. receptor that is a ligand- gated chloride-
selective ion channel.  GABA is the most common CNS inhibitory neurotransmitter; which 
reduces excitability of neurons and produces a calming effect on the brain, especially in the 
limbic, hypothalamic, and thalamic systems which are associated with behavior and emotion. 8,18  
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Midazolam is a water-soluble short acting, high potency benzodiazepine that provides sedative, 
anxiolytic, amnestic, and hypnotic effects.   Oral peak onset is 10-20 minutes with a half-life 2.2 
to 6.8 hours.   The major metabolite is α-hydroxymidazolam and is considered to be just as 
potent as midazolam.  Diazepam is a lipid soluble long acting, medium potency benzodiazepine 
that provides anxiolytic, muscle relaxing, anticonvulsant, and amnestic effects.  The oral (per os, 
PO) peak onset is 30-90 minutes with a half-life of ~18 hours in children 3 to 8 years old.  There 
are multiple active metabolites of diazepam with the major metabolites being 
desmethlydiazepam, temazepam, and oxazepam, which are associated with the prolonged half-
life of diazepam9.  Midazolam is considered to be 1.5 to 2 times more potent than diazepam and 
has a higher risk of adverse respiratory events.8–10,14,15,17–19   This potency is related to the water 
solubility of midazolam; midazolam is a low pH racemic solution of open and closed ring forms 
of the drug; once midazolam is systemically absorbed, it rapidly converts to a lipophilic closed 
ring (physiologically active) form of midazolam and has two times the affinity for GABAA 
receptors than diazepam.10,20,21  
The primary concern with using diazepam is related to its long elimination half-life, but 
what is often overlooked is the blood brain distribution (sedation) half-life, which is 2 hours 
compared to midazolam’s distribution half-life of 1 hour.19,22  Distribution half-life accounts for 
onset and duration of sedation; following absorption, serum concentrations are high and the drug 
will be distributed to tissues into degree of perfusion: brain, muscle, and then adipose. As drug 
distribution proceeds, serum levels decline, and high concentrations in the brain redistribute into 
the blood stream and into subsequent other tissues. These processes occur more rapidly with 
highly lipid soluble drugs and account for the shorter duration of sedation seen in both 
midazolam and diazepam.14,19  Drug elimination half-life is more closely associated with water 
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solubility, which is why midazolam (water soluble) has a significantly shorter elimination half -
life when compared with diazepam (lipid soluble) due to quicker processing by the liver and less 
active metabolites.14,20   
The emotions of fear and anxiety often hold the behaviors of aggression and hostility in 
check, but the ingestion of a benzodiazepine or other anxiolytic drugs may produce a paradoxical 
increase in aggression once GABA inhibition has provided an anxiolytic effect.8,17 Midazolam’s 
higher affinity for GABA receptors causes chloride channels to remain open longer, which 
increases the accumulation of GABA on the presynaptic clefts, which could subsequently induce 
extrapyramidal effects as the drug wears off.16,20   Any sedative anxiolytic could have side effects 
of agitation and irritability, however diazepam may reduce these adverse reactions due to its 
higher affinity for GABA antianxiety sub-receptors and has even been used to treat midazolam 
agitation reactions when reversal drugs (flumazenil) have previously failed to improve such 
agitations & combativeness.21,23   Such agitations with behavior may be the difference between 
successfully completing treatment or aborting the sedation.24  Preoperative diazepam has been 
shown to show less emergence agitation from general anesthesia when compared with 
preoperative midazolam.25   Nathan and Vargas reported higher agitation rates with higher single 
doses of midazolam and lower rates of agitation with lower doses of midazolam in combination 
with high dose meperidine and longer working time.26  These side effects (inconsolable crying, 
restlessness, and agitation)27 may be linked with less than harmonious sedations and may alter 
parents’ perceptions of how the overall sedation experience was for their child.28   
 Much of the sedation research does not address the rates of agitation, irritability, intra-
operative & post-operative behavior, & routinely does not account for adequate working time of 
oral diazepam.29  Diazepam has been reported to treat hallucinations, tremors, alcohol 
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withdrawals, midazolam withdrawal agitation, and to reduce general anesthesia emergence 
agitations.23,25  Considering these benefits of diazepam and its reduced risk of respiratory 
depression, a further look at its efficacy in pediatric dental sedation as a midazolam alternative is 
needed.   
 In 2016, Parents rated sedation as the most acceptable form of advanced behavior 
guidance techniques.30  Promoting cooperative behavior is the ultimate goal of sedation in order 
to safely complete dental treatment.31  The majority of oral sedation studies utilize one or both of 
the Frankl Scale, and the Houpt Scale as their standardized rating scales. The Frankl Scale is 
used to measure overall behavior ranging from one to four, with one being the worst behavior 
and four being the best behavior (Appendix 1).32  The Houpt Scale is divided into various 
categories including sleep, movement, and crying to allow for a more precise measurement in 
which lower scores mean poor behavior and higher scores mean better behavior (Appendix 2).33   
 The purpose of this study is to compare the effect of the moderate oral sedation triple 
combination of hydroxyzine and meperidine with either diazepam or midazolam in the 
management of pediatric dentistry patients both intra-operatively and in the post-operative 
period.  
 
Definition of Terms  
1) Midazolam Triple = Mi+M+H = Midazolam, Meperidine, Hydroxyzine triple 
combination regimen  
2) Diazepam Triple = Di+M+H = Diazepam, Meperidine, Hydroxyzine triple 
combination regimen  
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Methods 
 
This study was a randomized double-blind study of moderate oral sedation for dental 
treatment conducted at the Virginia Commonwealth University (VCU) School of Dentistry, 
Department of Pediatric Dentistry.  This Protocol was approved by the VCU Institutional Review 
Board, Committee for Human Research as VCU IRB HM20006549-Amendment 3 on April 3, 
2018.  
 Sample Criteria 
This study was an amended update to a pilot study at VCU, which was conducted with a 
smaller sample size.34  In this study, we strived to have a larger sample size while comparing 
patients during their first sedation appointment only.  Forty participants between the ages of 
three and seven who are already treatment planned for oral moderate sedation were enrolled in 
the study for completion of their dentistry from June 2017 through February 2019.   Patient 
participants for oral moderate sedation must have an ASA classification of I or II with tonsil 
hypertrophy less than 50% as characterized by Brodsky ratings of zero to two.  Patients with 
refractory or fearful behavior documented by Frankl scores of 1 to 3 and Frankl 4 patients with 
significant dental needs (greater than 2 quadrants) and a history of dental anxiety were included 
in this study.   
Patients were required to obtain a history and physical examination by their primary care 
physician for oral sedation clearance and be fasting (nil per os, NPO) after midnight of the 
morning of sedation as required by VCU Pediatric Dentistry protocol.  Consents for the sedation 
and study participation were completed on the morning of the sedation appointment.  
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 Exclusion criteria for patients in this study, as also outline by the American Academy of 
Pediatric Dentistry (AAPD) guidelines for oral sedation35, include severe systemic disease, 
allergy to the sedation and anesthetic medications used for treatment, nasal obstruction, recent 
upper respiratory infections, limited neck movement, obesity, macroglossia, and tonsillar 
hypertrophy greater than 50%, ASA classes III or greater, special needs patients, and those with 
anatomic airway abnormalities or extreme tonsillar hypertrophy present issues that require 
additional considerations.  These patients were excluded from this study to decrease the risk of 
any complications and allow for better standardization of medication dosing.14,35   
Procedure 
 Participants were randomly assigned for sedation with either the diazepam triple regimen 
or the midazolam triple regimen for their first sedation only: 20 patients for each treatment 
group.  The randomization list was determined using random number generator in SAS EG v6.1 
to randomize the order of 20 patients for each treatment group in random blocks of 10.  If the 
participants needed a second visit, the second sedation was not studied to allow for optimization 
based off of their previous sedation history.  The pediatric dental resident and faculty attending 
were aware of the triple combinations given, however, the sedation monitor, participant and 
parent were blind to the combination given for treatment.  The reversal agents for both 
combinations were the same, flumazenil for the benzodiazepines (diazepam and midazolam) and 
naloxone for meperidine.  Calculations based on the child’s weight of maximum local anesthetic 
delivery, oral sedation medication dosages and reversal agents were done prior to delivery of 
medication.   
 The diazepam triple regimen included diazepam, hydroxyzine and meperidine, and the 
midazolam triple regimen included midazolam, hydroxyzine and meperidine.  Each of the 
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medications used are marketed and approved by the FDA for use orally, and for use in 
combination with other medications.  The medication dosages were tailored individually based 
on the participant’s weight as follows: 
 Diazepam Triple Regimen 
 1. Meperidine (Demerol) - narcotic/opioid, 1.5-2.0mg/kg, 50 mg max 
 2. Hydroxyzine HCl (Atarax) - antihistamine, 1.5-2.0mg/kg, 50 mg max 
 3. Diazepam (Valium) - benzodiazepine, 0.2-0.3mg/kg, 10 mg max17,29 
 Midazolam Triple Regimen 
 1. Meperidine (Demerol) - narcotic/opioid, 1.5-2.0mg/kg, 50 mg max 
 2. Hydroxyzine HCl (Atarax) - antihistamine, 1.5-2.0mg/kg, 50 mg max 
 3. Midazolam (Versed) - benzodiazepine, 0.5-0.75mg/kg, 15 mg max26,36,37 
   
 Vital signs (oxygen saturation, respiratory rate, heart rate, non-invasive blood pressure 
and end-tidal CO2) were monitored at the start of the procedure and every five minutes   
afterwards until treatment was complete and the patient was ready for discharge.  Nitrous oxide 
with oxygen was administered at concentrations ranging from 30% to 70%, as determined by 
provider for each child to potentiate the effects of the oral medications to attempt the desired 
level of sedation.  Behavior was evaluated using the Houpt Scale (Appendix 2) and Frankl Score 
(Appendix 1) by the monitor at three time points: 1) injection time, 2) start of procedure and 3) 
when 100% oxygen was administered at the completion of treatment (Appendix 3).  Analysis of 
the various treatment checkpoints and group types include Wilcoxon rank-sum test and chi-
squared test. For standardization of this study, treatment was initiated between 45 to 60 minutes 
after dosing to allow for adequate onset of meperidine and hydroxyzine, while also accounting 
for the patients’ level of sedation and behavior.38 Nitrous oxide was administered after 5 minutes 
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of 100 percent pre-oxygenation and was titrated to effect as deemed necessary by the provider 
for the procedure.  
 The patients were discharged once they met the discharge criteria per AAPD Guidelines 
which include:  airway patency is satisfactory and stable, patient is easily arousable, 
responsiveness is at or near pre-sedation level, protective reflexes are intact, patient can talk, 
patient can sit up unaided, and state of hydration is adequate.35  Postoperative instructions were 
explained to the guardian and participant and the patient was escorted via wheelchair to their car. 
 A postoperative phone call survey was completed within eight hours after discharge 
regarding the participant’s behavior in the car ride home and upon arrival home (Appendix 
4).  The questions included inquiry about sleep, memory, activity level, motor imbalance, 
nausea, emesis, and behavior.   
 All pediatric dental residents and faculty involved are certified in Pediatric Advanced 
Life Support (PALS) and Basic Life Support (BLS) training.  Also, emergency management 
training is conducted biannually. All personnel who participate as sedation monitors were 
calibrated for Houpt and Frankl scoring prior to the study to ensure accuracy and consistency of 
study measures.  
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Results 
Statistical Methods 
 Data was summarized using descriptive statistics. Differences among categorical 
variables were compared using Fisher’s Exact Chi-squared test. Difference in behavior measures 
and post-operative time spent sleeping were compared using Wilcoxon rank-sum tests. All 
analyses were performed in SAS EG v.6.1 with a significance level of 0.05. P-values between 
0.05 and 0.10 were deemed marginally statistically significant.  
Results 
 A total of 40 subjects were enrolled in the study, with equal allocation to midazolam 
(n=20) and diazepam (n=20). Demographics of all participants are given in Table 1.  There were 
no significant differences between the two groups in terms of age (p-value=0.4903) or gender (p-
value=0.7440).  
 Of the 40 attempted sedations, there were a total of 17 failures. Eleven of the 17 occurred 
with the midazolam triple and the remaining six were with diazepam triple. Resulting in failure 
rates of 30% for diazepam and 55% with midazolam, though this difference was not statistically 
significant (p-value=0.20). Failure was defined as aborted treatment, or deviation of treatment 
that lead to placement of sodium diamine fluoride, sedative fillings, or general anesthesia 
workup even if some of the planned treatment was successfully completed.  
Behavior Scores 
 Behavior scores were compared at injection, treatment, and procedure completion.  
Complete breakdowns of the scores are given in Table 2. Median scores were higher for 
diazepam triple than midazolam triple for all measures, though not all differences were 
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statistically significant. Frankl scores (Figure 1) were marginally significantly different at 
treatment initiation (p-value=0.0792) and procedure completion (p-value=0.0984). Houpt Sleep 
scores (Figure 2) were significantly higher for diazepam at injection (1 vs 2; p-value=0.0043) 
and treatment (1 vs 2; p-value=0.0152), but not at procedure completion (1 vs 2; p-
value=0.3537). Houpt Movement (Figure 3) scores were marginally higher for diazepam at 
treatment (2 vs 3; p-value=0.0670), and at oxygen (2 vs 3; p-value=0.0753), but not at injection 
(2 vs 3; p-value=0.2428). There were no differences in Houpt Crying scores at any of the time 
points (p-value>0.4). Total Houpt scores (Figure 4) were marginally significantly different at all 
time points (injection (p-value=0.1077), treatment (p-value=0.0877), oxygen (p-value=0.0825)). 
Total Houpt scores were higher for diazepam than midazolam for all time points (injection: 8.5 
vs 13; treatment: 8 vs 12.5; oxygen: 10 vs 14). Overall behavior scores (Figure 5) were 
significantly higher for diazepam at oxygen (2.5 vs 4.5; p-value=0.0470).  
Side Effects 
 Guardians were contacted within the first eight hours after discharge and questioned 
about the child’s behavior. A total of 33 guardians were reached and provided information 
regarding postoperative side effects (17 with midazolam and 16 with diazepam).  A summary of 
the side effects reported is given in Table 3 and Figure 6. Guardians reported marginally more 
abnormal behavior with midazolam (35% vs 6%; p-value=0.0854) and more difficulty walking 
(41% vs 13%; p-value=0.0822). Guardians reported significantly more sleeping in the car on the 
ride home for midazolam (71% vs 38%; p-value=0.0526). Guardians also reported that children 
treated with midazolam were significantly more likely to complain of or seem dizzy (36% vs 
0%; p-value=0.0184). Guardians also reported an estimated time the child slept (including car 
ride home and after arriving home). The estimated median total time slept was 45 minutes for 
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diazepam (IQR: 0-90 minutes) and 61 for midazolam (IQR: 25-120 minutes). Although 
guardians tended to report longer sleep times with midazolam, the difference was not statistically 
significant (p-value=0.2071). 
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Discussion 
 
Previous studies comparing benzodiazepines as single agents have noted statistical 
differences between the sedation effects of midazolam versus diazepam5; midazolam has shown 
to have a higher first pass effect, very short half-life, and higher potency (1.5-2 times more 
potent) when compared to diazepam.20  Studies regarding anesthesia induction have concluded 
that preoperative midazolam for pediatric anesthesia induction, sedates patients deeper, while 
diazepam is better at reducing anesthesia emergence agitation.25  Diazepam has a longer half-life 
that can remain in the system up to 48 hours, however the clinical effects of procedural sedation 
typically last for no more than 2 hours and have a tendency to transition patients into a more 
calming anti-anxiety state.16,17,21,22  The results from this study do show that moderate sedation 
with diazepam triple did result in more procedural sleep and resulted in more successful 
treatment outcomes.  One could argue, that the midazolam triple was not as effective due to the 
midazolam wearing off sooner, however our data showed median total Houpt scores for 
midazolam triple were highest at the completion of procedure (Figure 4) and if the wait times 
were shorter then we could have seen longer post-operative midazolam sleep times.  The crucial 
times in sedation when the patients are most likely to fail is at the time of injection and at the 
initiation of treatment due to placement of the rubber dam, dry-field isolator, or due to the 
unpleasant sounds of the dental handpiece.  During these two treatment phases, sleep was 
statistically significantly higher for diazepam and the data overall consistently showed higher 
scores for diazepam at all time points and variables measured.   Parental perception of how the 
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appointment went may be dictated by how their child’s mood appears once they return to the 
room after the procedure is complete.  At the completion of the procedure, diazepam triple’s 
Houpt overall behavior was significantly greater (Figure 5).  The postoperative surveys showed 
that with the VCU dosing protocols, patients slept less after discharge with diazepam triple 
combination than with midazolam triple combination.  The data did reflect our suspicions 
regarding the negative side effects of midazolam including restlessness, incidences of agitation, 
hallucination, and abnormal behavior, but was only marginally significant (Figure 6).   At this 
time there is significant research, supporting the use of midazolam, yet the higher drug cost, 
potential for paradoxical effects, and existing literature appear to be conflicting with VCU’s 
current Diazepam triple combination protocol & clinical success rates.    
 
Our study included several limitations, which could be improved upon in future studies.  
This study took place in a teaching residency and involved various resident dental operators and 
multiple resident sedation monitors.  All of the residents were calibrated for behavior scoring at 
multiple times during the study, which included their entrance into the residency program, one 
week prior to study initiation, 3 months into the study and at the 6 month study time, however no 
inter-rater agreement was done for scoring.  Ideally, the same resident or faculty member would 
have monitored the behavior scores for all of the sedations, however attempting to coordinate 
this within the residency program proved to be a cumbersome task and was not pursued.  
Another consideration for improving rater consistency would involve video tapping of the 
sedations and having multiple raters assess the behavior of each sedation blind to the drug 
regimen.  The age range of our study population, age 3 to 7, limited the number of study 
participants, but if future studies were to expand the age range, then we would recommend 
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comparing sedation outcomes within the various age groups.2   The postoperative phone calls 
proved to be challenging due to difficulty getting in touch with the guardians, and sometimes the 
guardian left the child to be watched by another relative or babysitter while returning to work, 
which lead to incomplete data for the postoperative phase of treatment.34  Higher sedation failure 
rates could be attributed to the lack of consistent provider between the sedation workup 
appointment and the sedation appointment within the residency program.  As training pediatric 
dental residents, assessing childhood behavior and gauging a child’s ability to cooperate with the 
planned dental sedation versus general anesthesia is an art and takes time to hone and may also 
account for the higher sedation failure rates.   
 Future studies should include larger sample size, wider range of age, an equal distribution 
of demographics, with more consistent operator and monitor personnel.  Diazepam’s longer half-
life suggests that greater emphasis is needed toward studying the postoperative effects as well as 
the attentive adult supervision necessary regarding midazolam’s effects on difficulty walking, 
respiratory depression, and abnormal behavior.4,17,19,28  Retrospective studies regarding diazepam 
triple and midazolam triple may provide better insight into the overall success of these regimens, 
rates of adverse events, trends in pre and postoperative dental visit behavior, assessing average 
treatment working times, determining average post-operative monitoring times, treatment 
completion rates, and post-operative sleep times. 
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Conclusion 
 
The diazepam, meperidine, hydroxyzine triple combination sedation regimen shows 
promising results as a successful alternative to midazolam triple combination. Longer 
postoperative monitoring may be required with diazepam, but this study has shown postoperative 
sleep times to be less than previously reported. A larger sample size is needed to determine if the 
current trend will be maintained. 
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Tables 
 
Table 1: Sample Demographics 
  
Midazolam 
(n=20) 
Diazepam 
(n=20) Total (n=40) P-value* 
Age (mean, SD) 5.4, 1.35 5.1, 1.32 5.3, 1.3 0.4903 
Gender (n, %)      
Male 7, 35% 8, 40% 15, 38% 0.7440 
Female 13, 65% 12, 60% 25, 63%   
*P-value from t-test or Chi-squared test  
 
Table 2: Median Behavior Scores by Treatment 
  
Midazolam 
(n=20) 
Diazepam 
(n=20) 
P-
value* 
Frankl     
Injection 2 (1.5, 3) 3 (2, 4) 0.1903 
Treatment 3 (1, 3) 3.5 (2, 4) 0.0792 
Oxygen 2 (1, 2) 3 (1.5, 4) 0.0984 
Houpt     
Houpt: Sleep     
Injection 1 (1, 1.5) 2 (1, 3) 0.0043 
Treatment 1 (1, 2) 2 (1, 2) 0.0152 
Oxygen 1 (1, 2) 2 (1, 2) 0.3537 
Houpt: Movement     
Injection 2 (1.5, 3) 3 (2, 3.5) 0.2428 
Treatment 2 (1, 3) 3 (2, 3.5) 0.0670 
Oxygen 2 (2, 3) 3 (3, 4) 0.0753 
Houpt: Crying     
Injection 3 (2, 4) 3.5 (2, 4) 0.8672 
Treatment 2 (2, 4) 3 (2, 4) 0.5748 
Oxygen 3 (2, 4) 3.5 (2.5, 4) 0.4701 
Houpt: Total     
Injection 8.5 (7.5, 12) 13 (8, 15) 0.1077 
Treatment 8 (6.5, 13) 12.5 (8, 15) 0.0877 
Oxygen 10 (6.5, 12) 14 (9.5, 15) 0.0825 
Overall     
Injection 3 (2, 4) 4 (2.5, 5) 0.1517 
Treatment 3 (1, 5) 4 (2.5, 5) 0.1442 
Oxygen 2.5 (1, 4.5) 4.5 (2.5, 5.5) 0.0470 
*P-value from Wilcoxon Rank Sum Test 
†Indicates significant difference at 0.10 level    
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Table 3: Side Effects Reported by Guardians at 8 Hour Post Op Call 
  
Midazolam 
(n=20) 
Diazepam 
(n=20) P-value* 
Exhibit Any Abnormal Behavior 6, 35% 1, 6% 0.0854 
Fall asleep on the car ride home 12, 71% 6, 38% 0.0526 
Did your child snore (in car)? 2, 12% 0, 0% 0.4848 
Was it difficult to awaken your child when you arrived 
home? 3, 18% 0, 0% 0.2273 
Sleeping at Home 10, 59% 6, 38% 0.3028 
Did your child snore (at home)? 0, 0% 1, 6% 0.1026 
Have difficulty walking 7, 41% 2, 13% 0.0822 
Complain of or seem dizzy? 6, 36% 0, 0% 0.0184 
Play at Home 4, 24% 8, 50% 0.1571 
Have any memory of what happened in the dental office? 5, 29% 2, 13% 0.1577 
Nausea 3, 18% 1, 7% 0.6029 
Vomit 0, 0% 0, 0% N/A 
Have an upset stomach? 1, 6% 1, 6% 1.0000 
*P-value from Fisher’s Exact Test; N/A where no events were reported and therefore no test was 
conducted 
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Figures 
 
Figure 1: Median Frankl Score at Various Treatment Stages 
 
†Indicates significant difference at 0.10 level 
Figure 2: Median Houpt Sleep Scores 
 
††Indicates significant difference at 0.05 level 
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Figure 3: Median Houpt Movement Scores at Various Treatment Stages 
 
†Indicates significant difference at 0.10 level 
 
Figure 4: Median Total Houpt Scores at Various Treatment Stages 
 
†Indicates significant difference at 0.10 level 
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Figure 5: Median Houpt Overall Behavior Score 
 
††Indicates significant difference at 0.05 level 
Figure 6: Guardian Reported Side Effects at 8 Hour Post Op Call 
 
†Indicates significant difference at 0.10 level 
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Appendix 
Appendix 1: Frankl Behavior Scale 
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Appendix 2: Houpt Behavior Rating Scale 
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Appendix 3: Monitor Behavior Scale Rating Sheet 
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Appendix 4: Post Op Phone Call Survey 
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